Whitehawk Therapeutics (NASDAQ:WHWK – Get Free Report) and Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, risk, dividends, institutional ownership and profitability.
Risk & Volatility
Whitehawk Therapeutics has a beta of 0.81, suggesting that its share price is 19% less volatile than the S&P 500. Comparatively, Taysha Gene Therapies has a beta of 1.19, suggesting that its share price is 19% more volatile than the S&P 500.
Institutional and Insider Ownership
52.1% of Whitehawk Therapeutics shares are owned by institutional investors. Comparatively, 77.7% of Taysha Gene Therapies shares are owned by institutional investors. 49.9% of Whitehawk Therapeutics shares are owned by insiders. Comparatively, 3.5% of Taysha Gene Therapies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Whitehawk Therapeutics | $7.14 million | 30.30 | -$20.60 million | ($1.12) | -3.39 |
| Taysha Gene Therapies | $5.49 million | 282.47 | -$109.00 million | ($0.42) | -11.32 |
Whitehawk Therapeutics has higher revenue and earnings than Taysha Gene Therapies. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Whitehawk Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of recent ratings for Whitehawk Therapeutics and Taysha Gene Therapies, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Whitehawk Therapeutics | 1 | 1 | 6 | 0 | 2.62 |
| Taysha Gene Therapies | 1 | 0 | 12 | 2 | 3.00 |
Whitehawk Therapeutics presently has a consensus price target of $8.20, suggesting a potential upside of 116.07%. Taysha Gene Therapies has a consensus price target of $12.77, suggesting a potential upside of 168.54%. Given Taysha Gene Therapies’ stronger consensus rating and higher possible upside, analysts plainly believe Taysha Gene Therapies is more favorable than Whitehawk Therapeutics.
Profitability
This table compares Whitehawk Therapeutics and Taysha Gene Therapies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Whitehawk Therapeutics | N/A | -53.89% | -49.97% |
| Taysha Gene Therapies | N/A | -56.19% | -41.84% |
Summary
Taysha Gene Therapies beats Whitehawk Therapeutics on 9 of the 14 factors compared between the two stocks.
About Whitehawk Therapeutics
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.
About Taysha Gene Therapies
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
Receive News & Ratings for Whitehawk Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Whitehawk Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
